Adverse drug reactions associated with thalidomide treatment for oral mucosal diseases: a report of 44 cases
10.3760/cma.j.cn341190-20240204-00153
- VernacularTitle:沙利度胺治疗口腔黏膜疾病所致不良反应44例分析
- Author:
Xiaojuan XUE
1
;
Jing HUANG
;
Bin FENG
;
Weigang WANG
;
Jiao YUE
;
Yanfei MA
;
Yao LIN
Author Information
1. 国家口腔疾病临床医学研究中心 解放军空军军医大学第三附属医院药剂科，西安 710032
- Keywords:
Mouth mucosa;
Mouth diseases;
Drug-related side effects and adverse reactions;
Adverse drug reaction reporting systems;
Drug monitoring;
Salidomide
- From:
Chinese Journal of Primary Medicine and Pharmacy
2024;31(10):1457-1462
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To analyze the categories, characteristics, and clinical symptoms of adverse reactions associated with thalidomide treatment for oral mucosal diseases, providing a reference for the safe use of this medication in patients.Methods:A cross-sectional study was conducted to retrospectively analyze the adverse reactions to thalidomide treatment in 44 patients with oral mucosal diseases who received treatment at the Third Affiliated Hospital of Air Force Medical University from January 2019 to December 2023. The correlation between the age and sex of patients experiencing adverse reactions, the timing of these reactions in relation to sex, the organs and their appendages affected by the adverse reactions, and the outcomes of these reactions were statistically analyzed.Results:The incidence of adverse reactions associated with thalidomide treatment at the hospital was 0.21% (44/21 329), with a higher prevalence among female patients. Multiple organs were affected in 50.00% (22/44) of the cases, though the reactions were relatively concentrated, primarily involving the skin and its appendages, the central and peripheral nervous systems, and the gastrointestinal system. The main manifestations included rash and dizziness.Conclusion:In the treatment of oral mucosal diseases with thalidomide, it is essential to monitor adverse drug reactions, particularly those affecting the nervous system. Special attention should be given to the potential teratogenicity of thalidomide in individuals of childbearing age. In addition, it is vital to consistently investigate strategies to ensure the safety of patients using medication at home.
